ArticleEuropean journal of clinical pharmacology2004
Genetic polymorphism of cytochrome P450 2C9 in diphenylhydantoin-induced cutaneous adverse drug reactions.
Article in European journal of clinical pharmacology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 91 citations in OpenAlex.
- Patch testing for the diagnosis of anticonvulsant hypersensitivity syndrome: a systematic review.Drug safety · 2009Pooled it
- Risk factors for drug hypersensitivity reactions in children.Italian journal of pediatrics · 2024Review
- High and variable population prevalence of HLA-B*56:02 in indigenous Australians and relation to phenytoin-associated drug reaction with eosinophilia and systemic symptoms.British journal of clinical pharmacology · 2019Article
- Categorization and association analysis of risk factors for adverse drug events.European journal of clinical pharmacology · 2018Review
- CYP2C9 polymorphisms in epilepsy: influence on phenytoin treatment.Pharmacogenomics and personalized medicine · 2018Review
- Influence of genetic and non-genetic factors on phenytoin-induced severe cutaneous adverse drug reactions.European journal of clinical pharmacology · 2017Article
- Frequencies of CYP2C9 polymorphisms in North Indian population and their association with drug levels in children on phenytoin monotherapy.BMC pediatrics · 2016Observational
- Evolving models of the immunopathogenesis of T cell-mediated drug allergy: The role of host, pathogens, and drug response.The Journal of allergy and clinical immunology · 2015Review
- Association analysis of CYP2C9*3 and phenytoin-induced severe cutaneous adverse reactions (SCARs) in Thai epilepsy children.Journal of human genetics · 2015Article
- Recent advances of pharmacogenomics in severe cutaneous adverse reactions: immune and nonimmune mechanisms.Asia Pacific allergy · 2015Review
- PharmGKB summary: very important pharmacogene information for human leukocyte antigen B.Pharmacogenetics and genomics · 2015Article
- HLA associations and clinical implications in T-cell mediated drug hypersensitivity reactions: an updated review.Journal of immunology research · 2014Review
- Applications of CYP450 testing in the clinical setting.Molecular diagnosis & therapy · 2013Review
- ABCC2 Haplotype is Associated With Antituberculosis Drug-Induced Maculopapular Eruption.Allergy, asthma & immunology research · 2012Article
- Polymorphisms of Aspirin-Metabolizing Enzymes CYP2C9, NAT2 and UGT1A6 in Aspirin-Intolerant Urticaria.Allergy, asthma & immunology research · 2011Article
- Biomarkers for antiepileptic drug response.Biomarkers in medicine · 2011Article
- NAT2, CYP2C9, CYP2C19, and CYP2E1 genetic polymorphisms in anti-TB drug-induced maculopapular eruption.European journal of clinical pharmacology · 2011Article
- Predictive value of the lymphocyte toxicity assay in the diagnosis of drug hypersensitivity syndrome.Molecular diagnosis & therapy · 2010Article
- Update on the Genetic Polymorphisms of Drug-Metabolizing Enzymes in Antiepileptic Drug Therapy.Pharmaceuticals (Basel, Switzerland) · 2010Review
- Influence of CYP2C9 and CYP2C19 genetic polymorphisms on phenytoin-induced neurological toxicity in Indian epileptic patients.European journal of clinical pharmacology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundApart from allergic mechanisms, a lack or mutation of metabolic enzymes may cause adverse drug reactions. Patch testing has rarely been useful in cutaneous adverse drug reactions (CADRs) induced by diphenylhydantoin (DPH). Genetic polymorphisms leading to altered metabolic processes of cytochrome P(450) (CYP) 2C9, a main metabolic enzyme for DPH, may be the pathological mechanism for certain cases of DPH-induced CADRs.
objectiveTo examine the effects of an altered CYP2C9 variant, CYP2C9*3, on DPH-induced CADRs.
methodsTen patients with DPH-induced CADRs were examined for CYP2C9 genetic polymorphisms. The results were compared with non-exposed controls and 39 neurological patients without DPH-induced CADRs despite exposure to DPH. The patients with DPH-induced CADRs were also patch tested with anti-epileptic drugs and the results were compared with 40 DPH-exposed and 58 non-exposed controls.
resultsA heterozygous CYP2C9*3 variant was found in three of the 10 DPH-induced CADR patients. The crude odds ratios (OR) of the patients compared with those of exposed and non-exposed controls were 167 and 71, respectively. Only one neurological patient, who had never taken DPH, showed the variant in both exposed (P=0.007) and non-exposed (P=0.001) controls. Positive patch-test results were displayed in three of the ten DPH-induced patients, but the patients with positive patch-test reactions to DPH differed from those with the CYP2C9*3 polymorphism. No patients and controls displayed a CYP2C9*2 variant.
conclusionA CYP2C9*3 variant could play a role in the proportion of patients with DPH-induced CADRs that differ from patients with DPH-induced CADRs showing positive patch-test results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.